Divi's Labs Surpasses Q4 Expectations, Yet Valuations Remain a Concern
Divi’s Laboratories significantly outperformed expectations in its latest quarter, reporting an 18% year-over-year (YoY) increase in revenue and a 50% rise in EBITDA. This growth was largely driven by the Custom Synthesis (CS) segment, which saw a 38% …